Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BHMT | Q93088 | 11/20 | 0.50 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.49 |
| ▸ | NOS2 | P35228 | 2/20 | 0.45 |
| ▸ | NOS3 | P29474 | 1/20 | 0.45 |
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL537841 | 1.00 | BHMT (0.50) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL6655681 | 1.00 | BHMT (0.50) | BHMTBHMT2NOS2NOS3NOS1 | |
| Phosphonic Acid SCHEMBL27587576 | 0.96 | BHMT (0.49) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL9436829 | 0.86 | ARG1 (0.47) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL5509931 | 0.86 | ARG1 (0.47) | BHMTBHMT2NOS2NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL8932134 | 0.84 | ARG1 (0.46) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL4316097 | 0.80 | GSR (0.46) | NOS2NOS3NOS1 | |
| SCHEMBL1504429 | 0.80 | GSR (0.46) | NOS2NOS3NOS1 | |
| SCHEMBL21067514 | 0.80 | GSR (0.46) | NOS2NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL8900288 | 0.79 | GSR (0.44) | NOS2NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2825208-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | Levicept Ltd. (GB) | 2015-01-21 | — | — | EP | claimed |
| WO-2013136078-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | LEVICEPT LTD (GB) | 2013-09-19 | — | — | WO | claimed |
| EP-1432440-A2 | ADJUVANTS FOR NUCLEIC ACID VACCINES | GLAXO GROUP LIMITED (GB) | 2004-06-30 | — | — | EP | claimed |
| WO-2003030935-A2 | ADJUVANTS FOR NUCLEIC ACID VACCINES | GLAXO GROUP LIMITED (GB) | 2003-04-17 | — | — | WO | claimed |
| EP-4712957-A2 | ISOANDROGRAPHOLIDE ANALOGS AND METHOD FOR TREATMENT USING THE SAME | Enveda Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | disclosed |
| EP-4699607-A2 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2026-02-25 | — | — | EP | disclosed |
| EP-4346818-B1 | SOLID DOSAGE FORMS AND DOSING REGIMENS COMPRISING (2R,3S,4S,5R)-4-[[3-(3,4-DIFLUORO-2-METHOXY-PHENYL)-4,5-DIMETHYL-5-(TRIFLUOROMETHYL) TETRAHYDROFURAN-2-CARBONYL]AMINO]PYRIDINE-2-CARBOXAMIDE | VERTEX PHARMA (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250353836-A1 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4629968-A1 | NOOTKATONE FOR THE TREATMENT OF PRURITUS | Enveda Therapeutics, Inc. (US) | 2025-10-15 | — | — | EP | disclosed |
| EP-4629974-A1 | NOOTKATONE FOR THE TREATMENT OF GUT OR ABDOMINAL PAIN | Enveda Therapeutics, Inc. (US) | 2025-10-15 | — | — | EP | disclosed |
| WO-2024231899-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-11-14 | — | — | WO | disclosed |
| EP-1863757-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | Renovis, Inc. (US) | 2007-12-12 | — | — | EP | disclosed |
| WO-2007133637-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| EP-1853269-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | Renovis, Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
| WO-2007100758-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| WO-2006099410-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006093832-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| EP-1432440-A2 | ADJUVANTS FOR NUCLEIC ACID VACCINES | GLAXO GROUP LIMITED (GB) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003030935-A2 | ADJUVANTS FOR NUCLEIC ACID VACCINES | GLAXO GROUP LIMITED (GB) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353836-A1 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | TRPV1, SCN2A, SCN2B | BHMT 4030/4885BHMT2 2956/4885NOS2 3313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.